Tumor-specific delivery of BSH-3R for boron neutron capture therapy and positron emission tomography imaging in a mouse brain tumor model

Biomaterials

Volumn 56, Issue , 2015, Pages 10-17

  Iguchi, Yoshiya ^a   Michiue, Hiroyuki ^a   Kitamatsu, Mizuki ^b   Hayashi, Yuri ^a   Takenaka, Fumiaki ^a   Nishiki, Tei ichi ^a   Matsui, Hideki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KINKI UNIVERSITY   (Japan)

Author keywords

Boron neutron capture therapy (BNCT); Brain tumor; BSH poly arginine; CPP; DOTA; Glioma; PET; TAT

Indexed keywords

ARGININE; BRAIN; CELLS; CHELATION; CYTOLOGY; DISEASE CONTROL; NEUTRONS; PHARMACOKINETICS; POLYETHYLENE TEREPHTHALATES; POSITRONS; PROBES; SODIUM COMPOUNDS; TUMORS;

BORON NEUTRON CAPTURE THERAPY; BRAIN TUMORS; CLINICAL INVESTIGATION; DOTA; GLIOMA; METAL CHELATING AGENTS; PHARMACOKINETIC PROPERTIES; POSITRON EMISSION TOMOGRAPHY (PET);

POSITRON EMISSION TOMOGRAPHY;

ARGININE; BORON DERIVATIVE; CHELATING AGENT; COPPER 64; TETRAXETAN; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; BORON; BORONIC ACID DERIVATIVE; COPPER; OLIGOPEPTIDE; PEPTIDE; SINGLE HETEROCYCLIC RINGS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CANCER CELL; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; IN VITRO STUDY; MOUSE; NEUROIMAGING; NEUTRON CAPTURE THERAPY; NEUTRON RADIATION; NONHUMAN; PERIPHERAL VEIN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; BORON NEUTRON CAPTURE THERAPY; BRAIN NEOPLASMS; CANCER TRANSPLANTATION; CELL SURVIVAL; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MODEL; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ARGININE; BORON; BORON NEUTRON CAPTURE THERAPY; BORONIC ACIDS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; COPPER; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; GLIOMA; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84928385792     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.03.061     Document Type: Article

References (39)

1. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEngl J Med 2005, 352(10):987-996.
2. Kawabata S., Miyatake S., Kuroiwa T., Yokoyama K., Doi A., Iida K., et al. Boron neutron capture therapy for newly diagnosed glioblastoma. JRadiat Res 2009, 50(1):51-60.
3. Locher G.L. Biological effects and therapeutic possibilities of neutrons. Am J Roentgenol 1936, 36:1-13.
4. Coderre J.A., Morris G.M. The radiation biology of boron neutron capture therapy. Radiat Res 1999, 151(1):1-18.
5. Barth R.F. Boron neutron capture therapy at the crossroads: challenges and opportunities. Appl Radiat Isot 2009, 67(Suppl.7-8). S3-6.
6. Hatanaka H.A. revised boron-neutron capture therapy for malignant brain tumors J. Neurology 1975, 209:81-94.
7. Yamamoto T., Nakai K., Matsumura A. Boron neutron capture therapy in cancer: past, present and future. Cancer Lett 2008, 262(2):143-152.
8. Aihara T., Morita N., Kamitani N., Kumada H., Ono K., Hiratsuka J., et al. BNCT for advanced or recurrent head and neck cancer. Appl Radiat Isot 2014, 88:12-15.
9. Yanagie H., Higashi S., Seguchi K., Ikushima I., Fujihara M., Nonaka Y., et al. Pilot clinical study of boron neutron capture therapy for recurrent hepatic cancer involving the intra-arterial injection of a (10)BSH-containing WOW emulsion. Appl Radiat Isot 2014, 88:32-37.
10. Horiguchi H., Nakamura T., Kumada H., Yanagie H., Suzuki M., Sagawa H. Investigation of irradiation conditions for recurrent breast cancer in JRR-4. Appl Radiat Isot 2011, 69(12):1882-1884.
11. Tanaka H., Sakurai Y., Suzuki M., Masunaga S., Mitsumoto T., Kinashi Y., et al. Evaluation of thermal neutron irradiation field using a cyclotron-based neutron source for alpha autoradiography. Appl Radiat Isot 2014, 88:153-156.
12. Imahori Y., Ueda S., Ohmori Y., Kuzuki T., Ono K., Fujii R., et al. Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. JNucl Med 1998, 39:325-333.
13. Matsushita M., Tomizawa K., Moriwaki A., Li S.T., Terada H., Matsui H. Ahigh-efficiency protein transduction system demonstrating the role of PKA in long-lasting long-term potentiation. JNeurosci 2001, 21(16):6000-6007.
14. Michiue H., Tomizawa K., Wei F.Y., Matsushita M., Lu Y.F., Ichikawa T., et al. The NH2 terminus of influenza virus hemagglutinin-2 subunit peptides enhances the antitumor potency of polyarginine-mediated p53 protein transduction. JBiol Chem 2005, 280(9):8285-8289.
15. Michiue H., Tomizawa K., Matsushita M., Tamiya T., Lu Y.F., Ichikawa T., et al. Ubiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells. FEBS Lett 2005, 579(18):3965-3969.
16. Matsui H., Tomizawa K., Lu Y.F., Matsushita M. Protein therapy: invivo protein transduction by polyarginine (11R) PTD and subcellular targeting delivery. Curr Protein Pept Sci 2003, 4(2):151-157.
17. Michiue H., Eguchi A., Scadeng M., Dowdy S.F. Induction of invivo synthetic lethal RNAi responses to treat glioblastoma. Cancer Biol Ther 2009, 8(23):2306-2313.
18. Michiue H., Sakurai Y., Kondo N., Kitamatsu M., Bin F., Nakajima K., et al. The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide. Biomaterials 2014, 35(10):3396-3405.
19. Fujimura A., Michiue H., Cheng Y., Uneda A., Tani Y., Nishiki T., et al. Cyclin G2 promotes hypoxia-driven local invasion of glioblastoma by orchestrating cytoskeletal dynamics. Neoplasia 2013, 15(11):1272-1281.
20. Ueda Y., Wei F.Y., Hide T., Michiue H., Takayama K., Kaitsuka T., et al. Induction of autophagic cell death of glioma-initiating cells by cell-penetrating D-isomer peptides consisting of Pas and the p53 C-terminus. Biomaterials 2012, 33(35):9061-9069.
21. Feng B., Tomizawa K., Michiue H., Miyatake S., Han X.J., Fujimura A., et al. Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials 2009, 9:1746-1755.
22. Toyota T., Hanafusa T., Oda T., Koumura I., Sasaki T., Matsuura E., et al. Apurification system for 64Cu produced by a biomedical cyclotron for antibody PET imaging. JRadioanal Nucl Chem 2012, 298:295-300.
23. Hitsuda T., Michiue H., Kitamatsu M., Fujimura A., Wang F., Yamamoto T., et al. Aprotein transduction method using oligo-arginine (3R) for the delivery of transcription factors into cell nuclei. Biomaterials 2012, 33(18):4665-4672.
24. Feng B., Tomizawa K., Michiue H., Han X.J., Miyatake S., Matsui H. Development of a bifunctional immunoliposome system for combined drug delivery and imaging invivo. Biomaterials 2010, 31(14):4139-4145.
25. Savolainen S., Kortesniemi M., Timonen M., Reijonen V., Kuusela L., Uusi-Simola J., et al. Boron neutron capture therapy (BNCT) in Finland: technological and physical prospects after 20 years of experiences. Phys Med 2013, 29(3):233-248.
26. Pisarev M.A., Dagrosa M.A., Juvenal G.J. Boron neutron capture therapy in cancer: past, present and future. Arq Bras Endocrinol Metabol 2007, 51(5):852-856.
27. Ueda H., Tanaka H., Maruhashi A., Ono K., Sakurai Y. The optimization study of Bonner sphere in the epi-thermal neutron irradiation field for BNCT. Appl Radiat Isot 2011, 69(12):1657-1659.
28. Ambrosini V., Fanti S. 68Ga-DOTA-peptides in the diagnosis of NET. PET Clin 2014, 9(1):37-42.
29. Sugiyama Y., Yamashita S. Impact of microdosing clinical study - why necessary and how useful?. Adv Drug Deliv Rev 2011, 63(7):494-502.
30. Zheng M.Q., Nabulsi N., Kim S.J., Tomasi G., Lin S.F., Mitch C., et al. Synthesis and evaluation of 11C-LY2795050 as a K-opioid receptor antagonist radiotracer for PET imaging. JNucl Med 2013, 54(3):455-463.
31. Kawabata S., Hiramatsu R., Kuroiwa T., Ono K., Miyatake S. Boron neutron capture therapy for recurrent high-grade meningiomas. JNeurosurg 2013, 119(4):837-844.
32. Menichetti L., Cionini L., Sauerwein W.A., Altieri S., Solin O., Minn H. Positron emission tomography and [18F]BPA: a perspective application to assess tumour extraction of boron in BNCT. Appl Radiat Isot 2009, 67(Suppl.7-8). S351-4.
33. Ariyoshi Y., Shimahara M., Kimura Y., Ito Y., Shimahara T., Miyatake S.I. Fluorine-18-labeled boronophenylalanine positron emission tomography for oral cancers: qualitative and quantitative analyses of malignant tumors and normal structures in oral and maxillofacial regions. Oncol Lett 2011, 2(3):423-427.
34. Tamura K., Kurihara H., Yonemori K., Tsuda H., Suzuki J., Kono Y. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. JNucl Med 2013, 54(11):1869-1875.
35. Mortimer J.E., Bading J.R., Colcher D.M., Conti P.S., Frankel P.H., Carroll M.I. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET. JNucl Med 2014, 55(1):23-29.
36. Kageji T., Nagahiro S., Mizobuchi Y., Matsuzaki K., Nakagawa Y., Kumada H. Boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma: comparison of clinical results obtained with BNCT and conventional treatment. JMed Invest 2014, 61(3-4):254-263.
37. Suzuki M., Kato I., Aihara T., Hiratsuka J., Yoshimura K., Niimi M., et al. Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer. JRadiat Res 2014, 55(1):146-153.
38. Wittig A., Collette L., Moss R., Sauerwein W.A. Early clinical trial concept for boron neutron capture therapy: a critical assessment of the EORTC trial 11001. Appl Radiat Isot 2009, 67(Suppl.7-8). S59-62.
39. Miyatake S., Kawabata S., Kajimoto Y., Aoki A., Yokoyama K., Yamada M., et al. Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. JNeurosurg 2005, 103(6):1000-1009.